A Case of Interstitial Cystitis Associated with the Anti-Programmed- Death-Receptor-1 Inhibitor: Pembrolizumab
- Immune checkpoint inhibitors,
- Immune-related adverse events,
- Interstitial cystitis
Copyright (c) 2019 Dong
This work is licensed under a Creative Commons Attribution 4.0 International License.
Patients treated with antiprogrammed-death-receptor-1inhibitor (PD-1) often experience immune-related Adverse Events (irAEs). Hereby we report a case of nonbacterial interstitial cystitis in advanced NSCLC patient associated with Pembrolizumab before the ninth cycle started. With the use of immunosuppressive steroids, the symptoms disappeared immediately and then tapered gradually. The symptoms recurrent again when the immunotherapy restarted.